Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 77

1.

On the deviation from a Curie-Weiss behavior of the ZnFe2O4 susceptibility: A combined ab-initio and Monte-Carlo approach.

Melo Quintero J, Salcedo Rodríguez KL, Gómez Albarracín FA, Rosales HD, Mendoza Zélis P, Stewart SJ, Errico LA, Rodríguez Torres C.

Heliyon. 2019 Jan 28;5(1):e01170. doi: 10.1016/j.heliyon.2019.e01170. eCollection 2019 Jan.

2.

Rhetoric of representation: the disempowerment and empowerment of consumer leaders.

Scholz B, Stewart SJ, Bocking J, Happell B.

Health Promot Int. 2019 Feb 1;34(1):166-174. doi: 10.1093/heapro/dax070.

PMID:
29036568
3.

First-in-human phase 1 study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody, in patients with HER2-positive advanced solid tumors.

Bang YJ, Giaccone G, Im SA, Oh DY, Bauer TM, Nordstrom JL, Li H, Chichili GR, Moore PA, Hong S, Stewart SJ, Baughman JE, Lechleider RJ, Burris HA.

Ann Oncol. 2017 Apr 1;28(4):855-861. doi: 10.1093/annonc/mdx002.

4.

Alternative low-cost approach to the synthesis of magnetic iron oxide nanoparticles by thermal decomposition of organic precursors.

Perez De Berti IO, Cagnoli MV, Pecchi G, Alessandrini JL, Stewart SJ, Bengoa JF, Marchetti SG.

Nanotechnology. 2013 May 3;24(17):175601. doi: 10.1088/0957-4484/24/17/175601. Epub 2013 Apr 3.

PMID:
23548801
5.

Development of an Fc-enhanced anti-B7-H3 monoclonal antibody with potent antitumor activity.

Loo D, Alderson RF, Chen FZ, Huang L, Zhang W, Gorlatov S, Burke S, Ciccarone V, Li H, Yang Y, Son T, Chen Y, Easton AN, Li JC, Rillema JR, Licea M, Fieger C, Liang TW, Mather JP, Koenig S, Stewart SJ, Johnson S, Bonvini E, Moore PA.

Clin Cancer Res. 2012 Jul 15;18(14):3834-45. doi: 10.1158/1078-0432.CCR-12-0715. Epub 2012 May 21.

6.

Anti-tumor activity and toxicokinetics analysis of MGAH22, an anti-HER2 monoclonal antibody with enhanced Fcγ receptor binding properties.

Nordstrom JL, Gorlatov S, Zhang W, Yang Y, Huang L, Burke S, Li H, Ciccarone V, Zhang T, Stavenhagen J, Koenig S, Stewart SJ, Moore PA, Johnson S, Bonvini E.

Breast Cancer Res. 2011;13(6):R123. doi: 10.1186/bcr3069. Epub 2011 Nov 30.

7.

Phase 1 experience with an anti-glycotope monoclonal antibody, RAV12, in recurrent adenocarcinoma.

Burris HA 3rd, Rosen LS, Rocha-Lima CM, Marshall J, Jones S, Cohen RB, Kunkel LA, Loo D, Baughman J, Stewart SJ, Lewis N.

Clin Cancer Res. 2010 Mar 1;16(5):1673-81. doi: 10.1158/1078-0432.CCR-09-2263. Epub 2010 Feb 23.

8.

The formation of nanocrystalline SrFeO(3-delta) using mechano-synthesis and subsequent sintering: structural and Mössbauer studies.

Widatallah HM, Al-Rawas AD, Johnson C, Al-Harthi SH, Gismelseed AM, Moore EA, Stewart SJ.

J Nanosci Nanotechnol. 2009 Apr;9(4):2510-7.

PMID:
19437995
9.

Measuring satisfaction with social work services.

O'Brien MW, Stewart SJ.

Soc Work Health Care. 2009;48(2):105-18. doi: 10.1080/00981380802519404.

PMID:
19197769
10.

First XANES evidence of a disorder-order transition in a spinel ferrite compound: nanocrystalline ZnFe2O4.

Figueroa SJ, Stewart SJ.

J Synchrotron Radiat. 2009 Jan;16(Pt 1):63-8. doi: 10.1107/S0909049508032433. Epub 2008 Nov 14.

PMID:
19096176
11.

A software method for color compensation.

Stewart CC, Stewart SJ.

Curr Protoc Cytom. 2003 Feb;Chapter 10:Unit 10.15. doi: 10.1002/0471142956.cy1015s23.

PMID:
18770774
12.

Immunophenotyping.

Stewart CC, Stewart SJ.

Curr Protoc Cytom. 2001 May;Chapter 6:Unit 6.2. doi: 10.1002/0471142956.cy0602s00.

PMID:
18770715
13.

Titering antibodies.

Stewart CC, Stewart SJ.

Curr Protoc Cytom. 2001 May;Chapter 4:Unit 4.1. doi: 10.1002/0471142956.cy0401s14.

PMID:
18770707
14.

On the effect of nanocrystallization and disorder on the magnetic properties of Cu-rich, FeMnCu alloys.

Stewart SJ, Marco JF, Crespo P, Romero JJ, Martínez A, Hernando A, Palomares FJ, González JM.

J Nanosci Nanotechnol. 2007 Feb;7(2):610-7.

PMID:
17450803
15.

Influence of N-doping on the structure and electronic properties of titania nanoparticle photocatalysts.

Stewart SJ, Fernandez-García M, Belver C, Mun BS, Requejo FG.

J Phys Chem B. 2006 Aug 24;110(33):16482-6.

PMID:
16913779
16.

Skin penetration assessment of less lethal kinetic energy munitions.

Bir CA, Stewart SJ, Wilhelm M.

J Forensic Sci. 2005 Nov;50(6):1426-9.

PMID:
16382840
17.

Efficacy and safety of liposomal anthracyclines in phase I/II clinical trials.

Alberts DS, Muggia FM, Carmichael J, Winer EP, Jahanzeb M, Venook AP, Skubitz KM, Rivera E, Sparano JA, DiBella NJ, Stewart SJ, Kavanagh JJ, Gabizon AA.

Semin Oncol. 2004 Dec;31(6 Suppl 13):53-90. Review.

PMID:
15717738
18.

Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression.

Tripathy D, Slamon DJ, Cobleigh M, Arnold A, Saleh M, Mortimer JE, Murphy M, Stewart SJ.

J Clin Oncol. 2004 Mar 15;22(6):1063-70.

PMID:
15020607
19.

Multiparameter data acquisition and analysis of leukocytes.

Stewart CC, Stewart SJ.

Methods Mol Biol. 2004;263:45-66.

PMID:
14976360
20.

Cardiac dysfunction in the trastuzumab clinical trials experience.

Seidman A, Hudis C, Pierri MK, Shak S, Paton V, Ashby M, Murphy M, Stewart SJ, Keefe D.

J Clin Oncol. 2002 Mar 1;20(5):1215-21.

PMID:
11870163
21.

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer.

Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJ, Press M.

J Clin Oncol. 2002 Feb 1;20(3):719-26.

PMID:
11821453
22.

Personality and psychopathology profiles of veterans' wives: measuring distress using the MMPI-2.

Alessi MW, White Ray J, Ray GE, Stewart SJ.

J Clin Psychol. 2001 Dec;57(12):1535-42.

PMID:
11745594
23.

First-line Herceptin monotherapy in metastatic breast cancer.

Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJ.

Oncology. 2001;61 Suppl 2:37-42. Review.

PMID:
11694786
24.

First-line, single-agent Herceptin(R) (trastuzumab) in metastatic breast cancer. a preliminary report.

Vogel C, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJ.

Eur J Cancer. 2001 Jan;37 Suppl 1:25-29.

PMID:
11342197
25.

HLA class I antigen cell surface expression is preserved on acute myeloid leukemia blasts at diagnosis and at relapse.

Wetzler M, Baer MR, Stewart SJ, Donohue K, Ford L, Stewart CC, Repasky EA, Ferrone S.

Leukemia. 2001 Jan;15(1):128-33.

PMID:
11243380
26.

First-line, single-agent Herceptin(trastuzumab) in metastatic breast cancer: a preliminary report.

Vogel C, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJ; Genentech H0650 study investigators.

Eur J Cancer. 2001 Jan;37 Suppl 1:S25-9. Review.

PMID:
11167088
27.

Multiparameter data acquisition and analysis of leukocytes by flow cytometry.

Stewart CC, Stewart SJ.

Methods Cell Biol. 2001;64:289-312.

PMID:
11070845
28.

Cell preparation for the identification of leukocytes.

Stewart CC, Stewart SJ.

Methods Cell Biol. 2001;63:217-51. No abstract available.

PMID:
11060844
29.

Four color compensation.

Stewart CC, Stewart SJ.

Cytometry. 1999 Aug 15;38(4):161-75.

PMID:
10440854
30.

CD11b+CD28-CD4+ human T cells: activation requirements and association with HLA-DR alleles.

Chapman A, Stewart SJ, Nepom GT, Green WF, Crowe D, Thomas JW, Miller GG.

J Immunol. 1996 Dec 1;157(11):4771-80.

PMID:
8943378
31.

Tularemia: association with hunting and farming.

Stewart SJ.

FEMS Immunol Med Microbiol. 1996 Mar;13(3):197-99. No abstract available.

PMID:
8861028
32.

The use of directly and indirectly labeled monoclonal antibodies in flow cytometry.

Stewart CC, Stewart SJ.

Methods Mol Biol. 1995;45:129-47. No abstract available.

PMID:
7550676
33.

p185c-erbB-2 signal enhances cisplatin-induced cytotoxicity in human breast carcinoma cells: association between an oncogenic receptor tyrosine kinase and drug-induced DNA repair.

Arteaga CL, Winnier AR, Poirier MC, Lopez-Larraza DM, Shawver LK, Hurd SD, Stewart SJ.

Cancer Res. 1994 Jul 15;54(14):3758-65.

34.

Introduction: the proliferation and differentiation of macrophages.

Stewart CC, Riedy MC, Stewart SJ.

Immunol Ser. 1994;60:3-27. Review. No abstract available.

PMID:
8251576
35.

Multiparameter analysis of leukocytes by flow cytometry.

Stewart CC, Stewart SJ.

Methods Cell Biol. 1994;41:61-79. Review.

PMID:
7861980
36.

Cell preparation for the identification of leukocytes.

Stewart CC, Stewart SJ.

Methods Cell Biol. 1994;41:39-60. Review. No abstract available.

PMID:
7861972
37.
38.
39.

Immunological monitoring utilizing novel probes.

Stewart CC, Stewart SJ.

Ann N Y Acad Sci. 1993 Mar 20;677:94-112. Review. No abstract available.

PMID:
8494251
40.

Phytochrome Levels in Light-Grown Avena Change in Response to End-of-Day Irradiations.

Stewart SJ, Pratt LH, Cordonnier-Pratt IM.

Plant Physiol. 1992 Aug;99(4):1708-10.

41.

Activation of phospholipase D: a signaling system set in motion by perturbation of the T lymphocyte antigen receptor/CD3 complex.

Stewart SJ, Cunningham GR, Strupp JA, House FS, Kelley LL, Henderson GS, Exton JH, Bocckino SB.

Cell Regul. 1991 Oct;2(10):841-50.

42.

Avena sativa L. contains three phytochromes, only one of which is abundant in etiolated tissue.

Wang YC, Stewart SJ, Cordonnier MM, Pratt LH.

Planta. 1991 Apr;184(1):96-104. doi: 10.1007/BF00208242.

PMID:
24193935
43.
44.

Large-scale partial purification of phytochrome from green leaves of Avena sativa L.

Pratt LH, Shimazaki Y, Stewart SJ, Cordonnier MM.

Planta. 1991 Apr;184(1):81-6. doi: 10.1007/BF00208240.

PMID:
24193933
45.

A reliable method for northern blot analysis using synthetic oligonucleotide probes.

Henderson GS, Conary JT, Davidson JM, Stewart SJ, House FS, McCurley TL.

Biotechniques. 1991 Feb;10(2):190-7.

PMID:
1711871
46.
47.

Acute endotoxin-induced lymphocyte subset sequestration in sheep lungs.

Duke SS, Guerry-Force ML, Forbes JT, Stewart SJ, King G, Wickersham N, Brigham KL, Meyrick B.

Lab Invest. 1990 Mar;62(3):355-62.

PMID:
2179624
49.
50.

Resolving leukocytes using axial light loss.

Stewart CC, Stewart SJ, Habbersett RC.

Cytometry. 1989 Jul;10(4):426-32.

Supplemental Content

Loading ...
Support Center